These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8969323)

  • 21. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 23. PHARMAC seeks clinical feedback on its cost-utility analysis methodology.
    Grocott R; Moodie P
    N Z Med J; 2006 Aug; 119(1239):U2113. PubMed ID: 16912730
    [No Abstract]   [Full Text] [Related]  

  • 24. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.
    Casciano R; Tarride JE; Breton MC; Stern L; Langer A
    Can J Clin Pharmacol; 2004; 11(1):e179-90. PubMed ID: 15300960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The economic value of individualizing drug therapy.
    Navarro RP
    Manag Care Interface; 1997 Oct; 10(10):96-8. PubMed ID: 10174423
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA; Waterer GW; Barca R; Wunderink RG
    Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacist model of perceived responsibility for drug therapy outcomes.
    Planas LG; Kimberlin CL; Segal R; Brushwood DB; Hepler CD; Schlenker BR
    Soc Sci Med; 2005 May; 60(10):2393-403. PubMed ID: 15748686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What does economics have to offer risk-benefit analysis?
    Hurley J
    Can J Public Health; 1991; 82(3):S21-8, S45-53. PubMed ID: 1909209
    [No Abstract]   [Full Text] [Related]  

  • 31. Patients, more than physicians, frown on drug company freebies.
    Am J Health Syst Pharm; 1998 Sep; 55(17):1759. PubMed ID: 9775336
    [No Abstract]   [Full Text] [Related]  

  • 32. Meandering down the road to transparency.
    Carswell CI; Paladino JA
    Pharmacoeconomics; 2008; 26(3):179-80. PubMed ID: 18282012
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoepidemiology: a health imperative.
    MacLeod SM
    J Clin Epidemiol; 1991; 44(12):1285-6. PubMed ID: 1753258
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug therapy and monitoring: a team responsibility.
    Brands AJ; Brands AB
    Fam Community Health; 1983 Nov; 6(3):63-71. PubMed ID: 10263174
    [No Abstract]   [Full Text] [Related]  

  • 35. [Medication reconciliation: we all have a responsibility].
    Delgado Sánchez O; Martínez López I; Crespí Monjo M; Serra Soler G
    Farm Hosp; 2008; 32(2):63-4. PubMed ID: 18783703
    [No Abstract]   [Full Text] [Related]  

  • 36. Minimum Information About a Simulation Experiment (MIASE).
    Waltemath D; Adams R; Beard DA; Bergmann FT; Bhalla US; Britten R; Chelliah V; Cooling MT; Cooper J; Crampin EJ; Garny A; Hoops S; Hucka M; Hunter P; Klipp E; Laibe C; Miller AK; Moraru I; Nickerson D; Nielsen P; Nikolski M; Sahle S; Sauro HM; Schmidt H; Snoep JL; Tolle D; Wolkenhauer O; Le Novère N
    PLoS Comput Biol; 2011 Apr; 7(4):e1001122. PubMed ID: 21552546
    [No Abstract]   [Full Text] [Related]  

  • 37. The importance of predictive ADME simulation.
    Dickins M; Modi S
    Drug Discov Today; 2002 Jul; 7(14):755-6. PubMed ID: 12547029
    [No Abstract]   [Full Text] [Related]  

  • 38. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?
    Drummond MF
    Pharmacoeconomics; 1998 Jul; 14(1):1-9. PubMed ID: 10182189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Industry responsibility in interactive computer modeling.
    Mauskopf J
    Med Care; 1996 Dec; 34(12 Suppl):DS165-72. PubMed ID: 8969323
    [No Abstract]   [Full Text] [Related]  

  • 40. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.